The Peptic Ulcer Partnering report provides understanding and access to the peptic ulcer partnering deals and agreements entered into by the worlds leading healthcare companies. Read the full story
The Peptic Ulcer Partnering report provides understanding and access to the peptic ulcer partnering deals and agreements entered into by the worlds leading healthcare companies. Read the full story
The Irritable Bowel Syndrome Partnering report provides understanding and access to the irritable bowel syndrome partnering deals and agreements entered into by the worlds leading healthcare companies. Read the full story
The Crohn's Disease Partnering report provides understanding and access to the crohn's disease partnering deals and agreements entered into by the worlds leading healthcare companies. Read the full story
The Ulcerative Colitis Partnering report provides understanding and access to the ulcerative colitis partnering deals and agreements entered into by the worlds leading healthcare companies. Read the full story
The Inflammatory Bowel Disease Partnering report provides understanding and access to the inflammatory bowel disease partnering deals and agreements entered into by the worlds leading healthcare companies. Read the full story
The Gastrointestinal Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the gastrointestinal partnering deals and agreements entered into by the worlds leading healthcare companies. Read the full story
Salix Pharmaceuticals is a leading specialty pharmaceutical company, listed in the top 50 big biotech list by Current Partnering. Read the full story
Specialty Pharmaceuticals Company Salix Pharmaceuticals is committed to providing treatments for a wide spectrum of gastrointestinal disorders. Read the full story
Salix Pharmaceuticals has announced 3 M&A deals since 2009, with the deals being the acquisition of Santarus, Oceana Therapeutics and the merger between Salix and Cosmo Pharmaceuticals. Read the full story
Nektar Therapeutics stands to get $25 million from AstraZeneca's filing for Naloxegol, as part of previous pharma deals. Read the full story